Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
30 janv. 2024 08h00 HE
|
Annovis Bio Inc.
MALVERN, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing...
Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
24 janv. 2024 08h00 HE
|
Annovis Bio Inc.
MALVERN, Pa., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, has announced a...
Annovis Bio to Participate in the 139th Yale CEO Summit
11 déc. 2023 13h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...
Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
05 déc. 2023 07h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases today announced last...
Annovis Bio Appoints Andrew Walsh as Vice President Finance
01 déc. 2023 07h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s...
Annovis Bio Announces Full Enrollment of Its Phase II/III Alzheimer’s Disease Trial, Exceeding Original Projections
27 nov. 2023 07h30 HE
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s...
Annovis Bio Announces Third Quarter 2023 Financial Results and Provides Corporate Update
08 nov. 2023 17h00 HE
|
Annovis Bio Inc.
BERWYN, Pa., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases,...
Annovis Bio Announces Positive Interim Independent Analysis for Statistical Power in Its Alzheimer’s Study
12 oct. 2023 08h02 HE
|
Annovis Bio Inc.
BERWYN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a clinical-stage drug platform company addressing neurodegenerative diseases, today...
Annovis Bio to Present at the BIO CEO & Investor Digital Conference
16 févr. 2021 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...
Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report
17 déc. 2020 06h45 HE
|
Annovis Bio Inc.
BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other...